Valuation: Bioventix PLC

Market Cap 99.79M 134M 119M 110M 188M 12.61B 190M 1.32B 519M 6.63B 501M 491M 21.13B P/E 2026 *
14x
P/E 2027 * -
Enterprise Value 94.89M 127M 113M 105M 179M 11.99B 181M 1.26B 493M 6.3B 477M 467M 20.09B EV / Sales 2026 *
7.59x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
7.85%
Yield 2027 * -
1 day+2.09%
1 week+11.43%
Current month+14.71%
1 month+21.88%
3 months+25.81%
6 months+9.86%
Current year+2.36%
1 week 1,700
Extreme 1700
2,045
1 month 1,500
Extreme 1500
2,045
Current year 1,300
Extreme 1300
2,045
1 year 1,300
Extreme 1300
2,450
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 23/12/2003
Director of Finance/CFO 67 01/07/2020
Director TitleAgeSince
Director/Board Member 67 25/11/2010
Chairman 66 01/11/2004
Director/Board Member 67 01/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/04/26 Buy

Chief Financial Officer

66 0.0013%
20/04/26 Free

Chief Executive Officer

9,967 0.1908%
20/04/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
+2.09%+11.43%-14.47%-47.30% 133M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+6.53%+11.68%+90.35% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.32%+5.73%+26.68%+50.79% 44.09B
+1.88%+9.90%+22.35%+128.94% 43.72B
-1.24%+0.69%+264.29%+961.62% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+5.60%+36.60%+26.39% 23.37B
Average +0.61%+5.70%+45.84%+142.49% 38.76B
Weighted average by Cap. +0.48%+4.67%+51.58%+167.50%

Financials

2026 *2027 *
Net sales 12.5M 16.74M 14.92M 13.81M 23.55M 1.58B 23.83M 166M 64.98M 830M 62.81M 61.5M 2.65B -
Net income 7.1M 9.51M 8.47M 7.85M 13.38M 897M 13.54M 94.07M 36.91M 472M 35.67M 34.93M 1.5B -
Net Debt -4.9M -6.56M -5.85M -5.41M -9.23M -619M -9.34M -64.92M -25.47M -326M -24.62M -24.11M -1.04B -
Projected Income Statement - Annual - Bioventix PLC
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
21/10/26 GBX 1,950.00 +2.09% 27,846
20/10/26 GBX 1,910.00 +7.91% 21,696
19/10/26 GBX 1,770.00 -1.67% 24,818
16/10/26 GBX 1,800.00 +2.86% 7,548
15/10/26 GBX 1,750.00 0.00% 12,074
Trader
Investor
-
Global
-
Quality
ESG MSCI
CCC
MarketScreener Ratings - Bioventix PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19.10GBP
Average target price
39.00GBP
Spread / Average Target
+104.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bioventix PLC
  1. Stock Market
  2. Stocks
  3. BVXP Stock